Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Scancell Holdings (SCLP) Share News

UK AGM, EGM Calendar - Week Ahead

10th Oct 2014 14:48

Read More

UK AGM, EGM Calendar - Week Ahead

10th Oct 2014 05:26

Read More

UK AGM, EGM Calendar - Week Ahead

9th Oct 2014 15:15

Read More

UK AGM, EGM Calendar - Week Ahead

9th Oct 2014 05:26

Read More

UK AGM, EGM Calendar - Week Ahead

8th Oct 2014 14:58

Read More

UK AGM, EGM Calendar - Week Ahead

8th Oct 2014 05:26

Read More

UK AGM, EGM Calendar - Week Ahead

7th Oct 2014 15:05

Read More

Scancell Full-Year Loss Widens On Development, Administrative Costs

4th Sep 2014 09:36

Read More

UK MIDDAY BRIEFING: Serco CEO Bolsters Top Team Again

12th Aug 2014 11:14

Read More

UK WINNERS & LOSERS: Just Eat Delivers Tasty Revenue Growth

12th Aug 2014 11:03

Read More

Scancell Boosted By Positive Results SCIB1, PD-1 Combination

12th Aug 2014 08:12

Read More

UK MORNING BRIEFING: Just Eat Leads Mixed Market On Mobile Sales

12th Aug 2014 07:35

Read More

Scancell Granted US Patent For DNA Immunobody Technology

6th Jun 2014 08:52

LONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office. Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been gr Read More

UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data

2nd Jun 2014 10:39

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.<br />-------<br />FTSE 100 - WINNERS<br />-------<br /><strong>Anglo American</strong>, up 1.9%, <strong>Rio Tinto</strong>, up 1.7%, <strong>Glencore</strong>, up 1.4 Read More

Scancell Rises As It Gets More Good Results From Skin Cancer Treatment Trial

2nd Jun 2014 08:04

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "h Read More

Oxford Technology NAV Declines, Appealing VCT Status Withdrawal

27th May 2014 12:47

LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status. The trust posted a net asset value per share of 65 pence per share, down from 74 pence in t Read More

Scancell Holdings To Present Phase I/II ImmunoBody Trial Data At ASCO

15th May 2014 12:46

LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of Read More

UK MIDDAY BRIEFING: Lloyds Kicks Off Bank Season With Improvement

1st May 2014 13:03

LONDON (Alliance News) - <strong>Lloyds Banking Group</strong> kicked off the first-quarter bank earnings season Thursday, reporting that its pretax profit dropped by a third to GBP1.37 billion after last year was buoyed by gains on the sale of government securities.<br /><br />However, its un Read More

UK WINNERS & LOSERS: Lloyds Atop FTSE 100 Risers; Weir Leads Fallers

1st May 2014 11:27

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.<br />-------<br /><strong>FTSE 100 - WINNERS</strong><br />-------<br /><strong>Lloyds Banking</strong> Group, up 4.8%. The banking group is the biggest riser in the Read More

Scancell Rises As Long-Time Consultant Joins Its Board

1st May 2014 10:29

LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect. In a statement, the company, which is developing immunotherapies to treat Read More

FTSE 100 Latest
Value8,275.66
Change0.00